140
Participants
Start Date
October 2, 2019
Primary Completion Date
October 2, 2025
Study Completion Date
October 2, 2027
Indoximod
Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
Partial Radiation
Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
Full-dose Radiation
Palliative full-dose radiation plan to all known sites of disease (\>50 Gy to brain, \>45 Gy to spine).
Temozolomide
Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
Cyclophosphamide
Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Etoposide
Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Lomustine
Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
ACTIVE_NOT_RECRUITING
Emory University, Children's Heathcare of Atlanta, Druid Hills
RECRUITING
Augusta University, Georgia Cancer Center, Augusta
ACTIVE_NOT_RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
RECRUITING
MD Anderson Cancer Center, Houston
ACTIVE_NOT_RECRUITING
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Augusta University
OTHER
Emory University
OTHER
Theodore S. Johnson
OTHER